Objective: This study was conducted to evaluate the clinical efficacy and safety of Kang-ai injection combined with chemotherapy in the treatment of ovarian cancer. Methods: the databases of VIP, CNKI, WanFang, CBM, Pub Med, Cochrane Library and EMBASE were searched to collect the randomized controlled trials (RCTs) of Kang-ai injection, combined with chemotherapy versus chemotherapy alone for the treatment of ovarian cancer. The retrieval time was from the database setup to December 20, 2018. After two researchers independently screened the researches, extracted data and evaluated the risk of the included studies, the RevMan 5.3 software was used for analysis. A total of 8 RCTS were included. Results: Results showed that patients in Kang-ai injection combined with chemotherapy group were superior to the conventional chemotherapy group patients in total effective rate [RR = 1.31, 95% CI (1.11, 1.54), P = 0.001], quality of life [RR = 1.69, 95% CI (1.35, 2.13), P < 0.001], leukopenia [RR = 0.63, 95% CI (0.51, 0.77), P < 0.001], nausea and vomiting [RR = 0.41, 95% CI (0.24, 0.70), P = 0.001], decreased hemoglobin [RR = 0.50, 95% CI (0.28, 0.88), P = 0.002], and thrombocytopenia [RR = 0.45, 95% CI (0.24, 0.85), P = 0.01]. Conclusion: Kang-ai injection combined with chemotherapy for ovarian cancer is better than chemotherapy alone in improving total effective rate and quality of life, reducing the incidence of adverse reactions. Limited by the number and quality of included studies, the above conclusions are yet to be verified by more high-quality studies.